Bittersweet moment four our former students and now clinical research coordinators @MASLDResearch leaving and going to medical school! Couldn’t be more proud of them and love being able to play a small role in mentoring future generations of doctors 🙏 @AASLDtweets@pattymaysent
And just like that…
The time you do a Meet the Professor session on #NITs & therapeutics in #MASLD & #MASH@DDWMeeting with your former fellowship director.
Great session discussing diagnosis, risk stratification & treatment🙌
As #DDW2026 kicks off, we’re proud to highlight our @UCSD_GI team presenting oral and poster sessions. Grateful for the collaboration and innovation that made this possible. Looking forward to an inspiring conference!#MASLD@MASLDResearch@DrLoomba
1/ New review in @HepCommJournal by @PojsakornDan : The global epidemiology of alcohol-associated liver disease (ALD).
ALD is one of the most preventable causes of liver-related death worldwide — and the burden is set to surge.
A thread on what every clinician should know. 🧵
The future of hepatology: Preventing liver disease together with the public, scientists and artificial intelligence - JHEP Reports https://t.co/S8aP0IQuiH
Advances in genomic discovery are bringing precision medicine closer to the bedside.
In @AGA_Gastro, we explore the promise and pitfalls of genetics and emerging personalized therapeutics in hepatology.
@AjmeraVeeral, V Chen, R Reddy @AmerGastroAssn
https://t.co/d9tZaQ4Ith
1/6 🧵 In patients with ALD referred for early LT: cardiometabolic risk factors (CMRF) matter. In this multicentre cohort, CMRFs were linked to a lower chance of hepatic recompensation after referral. #LiverTwitter@UCSD_GI@MASLDResearch@AjmeraVeeral@DeepikaDevuniMD
Great CME hosted by Department of Hepatology, @pgichd.
Insightful discussion on recent advances in MASLD by @DrLoomba
Always inspiring to see the impactful work being led by @ajay_duseja .
As a trainee, grateful for the opportunity to learn from leaders in the field.
@drsuniltaneja@atulsachdeva@drnipunverma@drbabupgi
A new international consensus published in @AGA_Gastro establishes a unified framework for diagnosing and staging liver disease in α-1 antitrypsin deficiency.
Read more here: https://t.co/jEfPyqus87
@DrLoomba@MattiasMandorf1@AleksanderKrag@PaulYKwo
#ColorectalCancer is increasing among younger adults, making awareness & early screening more important than ever. Rohit Loomba, MD, #UCSDHealth, joined @CBS8 to discuss why screening matters, plus the key signs and symptoms you shouldn’t ignore.@DrLoomba https://t.co/rWLmerkBgN
Clinical utility of a 50% and 30% decline in MRI-PDFF in predicting fibrosis improvement in metabolic dysfunction-associated steatohepatitis - CGH https://t.co/i7gCTzmMGn
Our new paper on comparative efficacy of MASH therapies in cirrhosis- FGF-21, and combination therapies may be useful in reversing MASH cirrhosis-
@AASLDtweets@EASLnews@DrHuangDQ@MASLDResearch@UCSD_GI
Alimentary Pharmacology & Therapeutics | https://t.co/GQZqKLc1NM